Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Zevra Therapeutics (ZVRA) Receivables - Net (2018 - 2025)

Zevra Therapeutics' Receivables - Net history spans 8 years, with the latest figure at $23.3 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 121.32% year-over-year to $23.3 million; the TTM value through Dec 2025 reached $23.3 million, up 121.32%, while the annual FY2025 figure was $23.3 million, 121.32% up from the prior year.
  • Receivables - Net reached $23.3 million in Q4 2025 per ZVRA's latest filing, up from $16.8 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $23.3 million in Q4 2025 to a low of $100000.0 in Q3 2021.
  • Average Receivables - Net over 5 years is $8.4 million, with a median of $8.1 million recorded in 2022.
  • Peak YoY movement for Receivables - Net: plummeted 95.46% in 2021, then skyrocketed 1117.73% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $1.4 million in 2021, then soared by 484.03% to $8.3 million in 2022, then soared by 94.23% to $16.1 million in 2023, then plummeted by 34.8% to $10.5 million in 2024, then surged by 121.32% to $23.3 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Receivables - Net are $23.3 million (Q4 2025), $16.8 million (Q3 2025), and $18.3 million (Q2 2025).